Last reviewed · How we verify
BuCy
BuCy is a chemotherapy conditioning regimen combining busulfan and cyclophosphamide used to prepare patients for hematopoietic stem cell transplantation.
BuCy is a chemotherapy conditioning regimen combining busulfan and cyclophosphamide used to prepare patients for hematopoietic stem cell transplantation. Used for Conditioning regimen for hematopoietic stem cell transplantation in hematologic malignancies, Preparation for allogeneic or autologous bone marrow transplantation.
At a glance
| Generic name | BuCy |
|---|---|
| Sponsor | The First Affiliated Hospital of Soochow University |
| Drug class | Alkylating agent combination (chemotherapy conditioning regimen) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Busulfan is an alkylating agent that causes DNA cross-linking and cell death, while cyclophosphamide is a nitrogen mustard alkylating agent that also damages DNA. Together, they provide myeloablative conditioning to eliminate malignant cells and suppress the patient's immune system to allow engraftment of donor stem cells in transplant recipients.
Approved indications
- Conditioning regimen for hematopoietic stem cell transplantation in hematologic malignancies
- Preparation for allogeneic or autologous bone marrow transplantation
Common side effects
- Myelosuppression
- Mucositis
- Hepatotoxicity
- Nausea and vomiting
- Alopecia
- Graft-versus-host disease (GVHD)
Key clinical trials
- Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) (NA)
- Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study (PHASE2)
- CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (PHASE2)
- BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients (PHASE3)
- The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation (PHASE3)
- Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT (PHASE2)
- Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT (PHASE2)
- G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BuCy CI brief — competitive landscape report
- BuCy updates RSS · CI watch RSS
- The First Affiliated Hospital of Soochow University portfolio CI